Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

GambitBio is developing an at-home lateral flow test to screen for the most common cancers, empowering people to take control of their health and reduce the number of cancer-related deaths. Cancer Research Horizons recently interviewed CEO, Tiffany Ma, who co-founded the venture while completing her DPhil at the University of Oxford.

GambitBio seeks to develop an at-home, affordable saliva-based lateral flow test for early screening of prevalent cancers. The test detects proprietary biomarkers that target unique post-translational modifications in proteins and is designed to provide rapid results without the need for specialised equipment.

CEO and OxCODE researcher Dr Tiffany Ma began her PhD in The Department of Oncology in 2018. GambitBio was launched in 2023 as part of her entry for University of Oxford’s All-Innovate business idea competition.

Speaking to Cancer Research Horizons about the venture, Tiffany said: 'GambitBio exists to push for early detection and reduce the number of cancer-related deaths. We want people to be able to detect what is wrong earlier so clinicians can intervene and treat the problem sooner. Early detection can give people up to 95% survival rate over a 10-year period for certain cancer types.'


Read the full interview with Tiffany on the Cancer Research Horizon's website.